Encompass Health Raises Quarterly Dividend 10.5% to $0.21

Encompass Health Corporation raised its quarterly dividend 10.5% to $0.21 a share from $0.19. The shares traded ex-dividend on October 1, 2026, and the payment is due October 15, 2026. The new rate represents an annual dividend of $0.84 a share.

Why the dividend changed

Encompass Health did not identify a single trigger for the increase. Its regulatory filing placed the decision within a broader capital-allocation program funded through operating cash flow, cash on hand and borrowing capacity. The board also expanded the company’s share-repurchase authorization, signaling that the higher dividend was one part of a wider return-of-capital decision rather than an adjustment related to a stock split, merger or spin-off.

The increase followed a solid second quarter. Net operating revenue rose 9.6%, adjusted EBITDA increased 9.2% and operating cash flow advanced 4.6% from the prior-year quarter. Discharges grew 5.6%, while net patient revenue per discharge rose 3.9%. Encompass Health also increased its full-year revenue, adjusted EBITDA and adjusted earnings guidance after the quarter.

Adjusted free cash flow declined 4.8% in the quarter and 9.2% over the first six months, partly as the company continued investing in capacity. Encompass Health opened three hospitals totaling 139 beds during the first half and added 54 beds at existing hospitals. It expected to open five more hospitals and add more than 100 beds at existing facilities before year-end. Management has described the balance sheet and cash generation as providing flexibility to fund expansion, repurchases and dividends concurrently.

Dividend track record

The latest increase continues a recovery from earlier reductions, but the longer history is uneven. Annual payments were $0.89 a share in both 2020 and 2021. The total fell 9.9% to $0.80 in 2022 and fell another 25.3% to $0.60 in 2023, the last annual cut year. The 2024 record contains three payments totaling $0.47, a decline of 21.7%, so that total is not a clean four-payment comparison.

Payments began rebuilding in 2025. The annual total rose 48.9% to $0.70, with the quarterly rate moving from $0.17 to $0.19 during the year. Encompass Health then paid $0.19 for the first three 2026 ex-dividend dates before lifting the latest payment to $0.21. The company has two consecutive years of dividend growth, although its five-year annualized record remains a 5.3% annual decline. The pattern is one of recent restoration rather than uninterrupted long-term growth.

Is the dividend covered?

The dividend consumes 13% of earnings. That payout ratio indicates substantial accounting-earnings coverage and leaves most earnings available for hospital development, debt service, repurchases and other corporate needs.

SmarterDividends gives Encompass Health a dividend-safety score of 63 and a grade of C, meaning borderline within the 50-65 range. In plain terms, current earnings coverage is wide, but the overall assessment stops short of classifying the dividend as comfortably secure. The history of reductions and the company’s capital-intensive expansion program provide relevant context for that more guarded grade.

Yield and valuation

The forward yield is 0.69%, compared with a Healthcare sector median of 1.80%. The dividend therefore provides less current income than the sector benchmark despite the latest increase. At the annual rate of $0.84, every 100 shares produces $84.00 in annual income.

The shares were priced at $119.06, while SmarterDividends estimates fair value at $98.14. Its valuation verdict is overvalued, corresponding to 19% downside to fair value. That valuation assessment is separate from dividend coverage: the 13% earnings payout ratio measures the distribution’s burden on profits, while the fair-value comparison measures the share price against the estimate.

What to watch

The immediate milestone is the October 15, 2026 payment. After that, the next dividend amount and timetable remain subject to board approval. Encompass Health says future declarations will depend on its capital position and alternative uses of funds.

The next operating update will show whether the trends supporting the increase continued. Relevant items include discharge growth, revenue per discharge, labor and other hospital costs, adjusted free cash flow and progress on new hospitals and bed additions. Investors can also track whether Encompass Health maintains its raised full-year guidance while funding its development program, dividends and enlarged repurchase authorization. The balance among those uses of cash will provide the clearest evidence of how management is prioritizing capital after the increase.